Key takeaways
- Irish nutrition giant Glanbia hiked its full-year earnings growth forecast to 17%-20% following surging demand for its protein products.
- Sales of Glanbia's flagship Optimum Nutrition brand jumped 25% in the first half of 2026, driven in part by GLP-1 users seeking to prevent muscle loss.
- Surging demand is driving a double-digit percentage rise in global whey costs, prompting Glanbia to issue its third retail price hike since late 2025.
What happened
On August 6, 2026, Irish nutrition giant Glanbia upgraded its full-year earnings forecast following a major surge in demand for its protein products, driven in part by patients using GLP-1 weight-loss medications. The company raised its expected full-year adjusted earnings per share growth to a range of 17% to 20%, up from its previous late-April estimate of 7% to 11%.
Why it matters
The financial ripple effects of the GLP-1 boom are expanding far beyond pharmacy counters and telehealth platforms. Patients on medications like Wegovy and Zepbound are medically advised to consume high amounts of protein to preserve lean muscle mass during rapid weight loss.
This dietary shift is transforming the sports nutrition industry, driving traditional "gym-goer" supplements into mainstream supermarket aisles. However, the surging demand is also swallowing up global supplies of whey—a primary ingredient in protein powders—meaning GLP-1 patients will face higher out-of-pocket costs for essential nutritional support.
What the data says
The financial data released by Glanbia, as reported by Reuters, highlights the scale of this consumer shift:
- Sales Growth: Revenues for Glanbia's flagship Optimum Nutrition brand jumped 25% in the first half of 2026.
- Earnings Jump: Glanbia's adjusted earnings per share (EPS) surged by 30% in the first half of the year, driving the company to upgrade its full-year EPS growth forecast to 17%–20%.
- Market Response: Shares of Glanbia rose 6.1% to €23.90 in Dublin following the announcement, having nearly doubled in value over the preceding year.
- Rising Costs: Glanbia Chief Financial Officer Mark Garvey told Reuters that the company expects a "double-digit percentage rise" in whey costs for the rest of 2026 and into 2027.
- Price Hikes: To offset these rising raw material costs, Glanbia has already raised Optimum Nutrition prices twice since November 2025 and is implementing a third price hike this quarter.
Garvey acknowledged the direct connection to the weight-loss market, noting that "the increase in demand for protein in whatever format has been driven in some way by the significant increase in GLP-1 usage."
How it compares
For years, the high cost of GLP-1 therapy has dominated consumer discussions. Patients navigating top-rated online providers on platforms like our /providers directory or comparing clinical support via the U.S. News telehealth ratings often focus on the monthly price of the medication itself.
However, this development shows that the total cost of care is rising in unexpected ways. While patients can use our /compare tool to find affordable monthly medication plans, they must now budget more for necessary supportive nutrition. A container of premium whey protein that cost $60 last year may now cost closer to $75 or $80 due to compounding price hikes, adding a sneaky "protein tax" to the overall monthly cost of managing obesity.
How this fits the bigger picture
The surging demand for nutritional support reflects a broader trend of patients taking charge of their holistic health while on obesity medications. In our prior coverage of clinical platforms, such as the U.S. News rating of Found, we highlighted the growing importance of comprehensive clinical support, lifestyle coaching, and nutritional guidance over simply writing a prescription.
As millions of Americans access these medications, the agricultural and supplement supply chains are struggling to keep pace. The supply squeeze on whey protein mirrors the ongoing active pharmaceutical ingredient (API) shortages that have plagued brand-name drugs, driving many patients toward alternative clinical options. Just as supply constraints have reshaped how patients obtain their physical medications, global ingredient shortages are now threatening to raise the everyday cost of staying healthy while on them.
What happens next
Consumers should prepare for immediate price increases on popular protein powders, shakes, and bars, with Glanbia's scheduled price hike taking effect this quarter.
Over the next year, the industry will watch whether rival supplement manufacturers follow suit with their own price hikes as global whey prices continue their projected double-digit percentage climb through 2027. Additionally, expect telehealth providers and GLP-1 programs to increasingly partner with supplement brands or launch their own proprietary, high-protein companion products to capture a share of this booming wellness market.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare provider before starting any weight-loss medication or making major changes to your diet and supplement regimen.